In Vitro Studies to Evaluate the Intestinal Permeation of an Ursodeoxycholic Acid-Conjugated Oligonucleotide for Duchenne Muscular Dystrophy Treatment.
DMD myotubes
Duchenne muscular dystrophy
IEC-6 cells
antisense oligonucleotides
co-culture
conjugated oligonucleotides
exon skipping
exosomes
intestinal permeation
ursodeoxycholic acid
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
received:
04
07
2024
revised:
24
07
2024
accepted:
29
07
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
Delivery represents a major hurdle to the clinical advancement of oligonucleotide therapeutics for the treatment of disorders such as Duchenne muscular dystrophy (DMD). In this preliminary study, we explored the ability of 2'-
Identifiants
pubmed: 39204368
pii: pharmaceutics16081023
doi: 10.3390/pharmaceutics16081023
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : University of Ferrara
ID : 2022-FAR.L-DA_018, A.D.; 2022-FAR.L-PB_001, B.P.; 2022-FAR.L-PD, D.P.; 2022-FAR.L-BM, M.B., 2021-FIRD M.B. and 2021-DOTT-DM-1061_FM_01_RIC, M.B